Daniel Heudobler
Impact in
- Immunology top 10%
- Immune cells in cancer
- Atherosclerosis and Cardiovascular Diseases
- Immune Cell Function and Interaction
- Immunotherapy and Immune Responses
- Oncology top 10%
- CAR-T cell therapy research
Papers in
- Oncology 17
- CAR-T cell therapy research 6
- Cancer Immunotherapy and Biomarkers 5
-
- Acute Myeloid Leukemia Research 5
- Co-authors
- Albrecht Reichle (21 shared papers)Wolfgang Herr (21 shared papers)Florian Lüke (19 shared papers)Tobias Pukrop (17 shared papers)Christopher Gerner (6 shared papers)Martin Vogelhuber (12 shared papers)Lina Ghibelli (7 shared papers)Sebastian Klobuch (7 shared papers)
In The Last Decade
Daniel Heudobler
45 papers receiving 1.1k citations
Daniel Heudobler's Hit Papers
Peers
Comparison fields: 5 of 93
- Immunology 355
- Oncology 294
- Cancer Research 132
- Hematology 88
- Molecular Biology 443
Countries citing papers authored by Daniel Heudobler
This map shows the geographic impact of Daniel Heudobler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Heudobler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Heudobler more than expected).
Fields of papers citing papers by Daniel Heudobler
This network shows the impact of papers produced by Daniel Heudobler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Heudobler. The network helps show where Daniel Heudobler may publish in the future.
Co-authors
The 25 scholars most cited alongside Daniel Heudobler, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 54 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2012 | 501 | |
| 2 | CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial Hit paper breakdown → | 2023 | 210 |
| 3 | 2007 | 48 | |
| 4 | 2018 | 44 | |
| 5 | 2019 | 34 | |
| 6 | 2020 | 28 | |
| 7 | 2018 | 26 | |
| 8 | 2015 | 20 | |
| 9 | 2022 | 19 | |
| 10 | 2018 | 18 | |
| 11 | 2019 | 15 | |
| 12 | 2018 | 15 | |
| 13 | 2015 | 14 | |
| 14 | 2022 | 10 | |
| 15 | 2021 | 10 | |
| 16 | 2024 | 10 | |
| 17 | 2021 | 10 | |
| 18 | 2018 | 9 | |
| 19 | 2021 | 9 | |
| 20 | 2022 | 8 |
About Daniel Heudobler
Daniel Heudobler is a scholar working on Oncology, Hematology, Immunology, Pathology and Forensic Medicine and Cancer Research, having authored 54 papers that have together received 1.1k indexed citations. Recurring topics across this work include CAR-T cell therapy research (6 papers), Cancer Immunotherapy and Biomarkers (5 papers), Acute Myeloid Leukemia Research (5 papers), Lymphoma Diagnosis and Treatment (5 papers), Cancer Genomics and Diagnostics (4 papers), Immunotherapy and Immune Responses (4 papers), Lung Cancer Treatments and Mutations (4 papers) and Retinoids in leukemia and cellular processes (3 papers). The work is most often cited by research in Immunology (355 citations), Oncology (294 citations), Cancer Research (132 citations), Hematology (88 citations) and Molecular Biology (443 citations). Daniel Heudobler has collaborated with scholars based in Germany, Italy and Austria. Frequent co-authors include Albrecht Reichle, Wolfgang Herr, Florian Lüke, Tobias Pukrop, Christopher Gerner, Martin Vogelhuber, Lina Ghibelli, Sebastian Klobuch, Dennis Christoph Harrer and Kirsten Utpatel. Their work appears in journals such as Frontiers in Oncology, Frontiers in Pharmacology, Annals of Oncology, Blood and Cancers.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.